History

Insulin was isolated by Frederick Banting and Charles Best at the University of Toronto in summer 1921 (with collaborators James Collip and J.J.R. Macleod), and the discovery was announced publicly in November 1921. The first human treatment came in January 1922: 14-year-old Leonard Thompson received the first Banting/Best extract on 11 Jan 1922, and Collip's purified extract on 23 Jan 1922 effectively stabilized his blood glucose — transforming type 1 diabetes from a death sentence into a manageable disease. Banting and Macleod received the 1923 Nobel Prize in Physiology or Medicine (sharing the prize money with Best and Collip), and the patent was sold to the University of Toronto for $1. Recombinant human insulin (Humulin, Genentech/Eli Lilly, produced in E. coli) received FDA marketing approval on 30 October 1982 — the first recombinant-DNA pharmaceutical ever approved for human use, cleared in roughly 5 months versus a then-average ~30 months.

Insulin sits at a strange intersection: it is simultaneously one of the most important, best-validated, life-saving drugs in all of medicine and one of the most acutely dangerous compounds misused in strength sports. For people with diabetes it is essential and irreplaceable. As a performance or “anabolic” tool in healthy people, the human record is overwhelmingly a record of harm — hypoglycemic coma, irreversible brain injury, and death — with no good controlled evidence that it actually builds meaningful muscle. This page is educational and harm-reduction oriented and contains no dosing, cycles, stacks, or sourcing information.

What it is

Insulin is a 51-amino-acid peptide hormone built from two chains (A and B) linked by disulfide bonds, with a molecular weight of about 5.8 kDa. It is secreted by the beta cells of the pancreatic islets of Langerhans and is the body’s primary anabolic and glucose-lowering hormone.

Mechanistically, insulin binds the insulin receptor, a transmembrane receptor tyrosine kinase. Receptor autophosphorylation activates the IRS/PI3K/Akt cascade, which (1) triggers translocation of GLUT4 glucose transporters to the cell membrane in muscle and adipose tissue, increasing glucose uptake; (2) stimulates glycogen synthesis (by inhibiting GSK3, which activates glycogen synthase); (3) promotes lipogenesis and inhibits lipolysis; and (4) drives amino-acid uptake and protein synthesis while suppressing proteolysis — the basis of its “anabolic” reputation. It also signals through the MAPK pathway, accounting for growth/mitogenic effects. The net result is lower blood glucose and a shift of the body into a fuel-storage, tissue-building state.

Therapeutic forms include recombinant human insulin and engineered analogs that differ in onset and duration: rapid-acting (lispro, aspart, glulisine), short-acting (regular), intermediate (NPH), and long-acting basal analogs (glargine, detemir, degludec).

The claims

In strength sports — bodybuilding and powerlifting in particular — insulin is misused for its anabolic effects. The rationale is physiologic: it drives glucose, amino acids, and creatine into muscle, enhances glycogen storage (the “muscle fullness”/pump effect), and suppresses protein breakdown. It is frequently combined with anabolic-androgenic steroids and growth hormone, on the (largely anecdotal) premise that insulin and GH/IGF-1 act synergistically on tissue growth.

A published case series of 41 non-diabetic insulin users (Ip et al., 2012) found users averaged about 30.7 years old, were 97.6% male, 95.1% also used anabolic steroids, and averaged roughly 16 different performance-enhancing drugs per year; about 81% said insulin was “easy” to acquire, from pharmacies and local/gym sources.

What the evidence actually shows

The evidence splits cleanly into two very different stories.

Medical (overwhelming). Insulin is unequivocally effective and life-saving for type 1 diabetes and a mainstay for advanced type 2 — among the best-established therapies in all of medicine, with a century of use behind it.

Performance/anabolic (essentially absent). There is no robust controlled human evidence that exogenous insulin meaningfully increases lean mass or strength in healthy, well-fed athletes. The “evidence” for this use is essentially case reports and one survey-based case series, not efficacy trials. The documented human literature on insulin in athletes is dominated by harm — severe hypoglycemia, coma, permanent brain injury (neuroglycopenia), and death. Ip et al. (2012) found that 56.8% of users reported hypoglycemic episodes, including a case of loss of consciousness, and individual case reports describe non-diabetic bodybuilders presenting in coma after self-injection. In short, the practice is driven by physiology and anecdote, and it carries the highest acute lethality risk of common PEDs.

Legal and regulatory status

US — prescription drug, not a controlled substance. All insulins are legitimate prescription (Rx) drugs regulated by the FDA. They are NOT controlled substances and are not scheduled under the Controlled Substances Act. Possession and use are legal with a prescription. FDA-approved indications include type 1 diabetes (where insulin is life-sustaining and mandatory), type 2 diabetes when other therapies are inadequate, gestational diabetes, and the management of diabetic ketoacidosis and hyperglycemic emergencies. Notably, the older “human” insulins — Regular, NPH, and 70/30 mixes (e.g., Novolin/ReliOn) — remain purchasable without a prescription via the pharmacist in nearly all US states (Indiana is the noted exception); the modern analogs (lispro, aspart, glargine, and the rest) are Rx. Obtaining or using insulin for non-medical performance enhancement is off-label/illicit misuse, but it is not a scheduling violation.

For contrast within the broader PED context:

DNP (2,4-dinitrophenol) kills people. It is NOT approved for human consumption. The FDA declared it unfit and extremely dangerous for human use in 1938 after a wave of cataracts (“dinitro-cataracts”), agranulocytosis, hyperthermia, and hundreds of deaths. It is now sold illicitly online as a “fat burner” and continues to cause fatal poisonings. It works by uncoupling mitochondrial oxidative phosphorylation, has a near-zero margin between an “effective” and a lethal dose, and has no specific antidote.
Mesterolone and fluoxymesterone are anabolic-androgenic steroids and are Schedule III controlled substances under the US Controlled Substances Act (Anabolic Steroids Control Act of 1990).

Anti-doping (WADA). Insulins (and insulin-mimetics) are prohibited under S4.4.2 (“Insulins and Insulin-Mimetics”) within the S4 Hormone and Metabolic Modulators class. S4 substances are prohibited at all times — both in- and out-of-competition. Diabetic athletes who medically require insulin must hold a Therapeutic Use Exemption (TUE). For related context, aromatase inhibitors and anti-estrogens/SERMs (e.g., tamoxifen, clomifene) also fall under S4 (S4.1–S4.3), and other metabolic modulators under S4.4 include AMPK activators/PPARδ agonists (S4.4.1), meldonium (S4.4.3), and trimetazidine (S4.4.4). DNP and anabolic steroids fall outside S4 — anabolic agents are class S1, and non-approved substances such as DNP can fall under S0 (Non-Approved Substances). All are likewise prohibited at all times.

Safety

Insulin is the most acutely dangerous compound among the PED-adjacent agents discussed here, because its principal toxicity is rapid, profound, and can be lethal within minutes to hours.

Hypoglycemia (the lethal risk). Exogenous insulin in a non-diabetic — or any insulin overdose — drives blood glucose dangerously low. Early signs are sweating, tremor, palpitations, hunger, and anxiety; as the brain is starved of glucose (neuroglycopenia), this progresses to confusion, slurred speech, seizures, coma, permanent brain damage, and death. Long-acting analogs are especially dangerous because their effect outlasts a single feeding and can cause delayed, prolonged, recurrent hypoglycemia. Strenuous exercise, fasting, and alcohol all amplify the risk. There is no margin for error: the difference between an “effect” and a fatal event can be small, and self-administration without glucose monitoring is potentially fatal. Survivors of severe episodes can be left with lasting cognitive and neurological deficits.
Other risks. Hypokalemia (insulin drives potassium intracellularly, which can provoke cardiac arrhythmias), injection-site lipohypertrophy, fat gain, and rare hypersensitivity. Counterfeit or shared “gym” insulin adds contamination and dosing-uncertainty risk.
Deliberate harm. Insulin is also a notorious instrument of deliberate harm, factitious illness, and homicide, precisely because it can be hard to detect post-mortem — underscoring how potent and silent its lethality is.

For comparative context only: DNP causes uncontrolled hyperthermia, multi-organ failure, has no antidote, and is frequently fatal. T3/liothyronine can cause cardiac arrhythmia/tachycardia, bone loss, and suppression of endogenous thyroid function. Aromatase inhibitors carry adverse bone-density and lipid/cardiovascular effects. SERMs carry venous thromboembolism/clot risk. Insulin’s defining danger is fatal hypoglycemia. None of this is medical advice.

Bottom line

Insulin is a 51-amino-acid peptide hormone and one of the genuine triumphs of modern medicine — essential and life-saving for type 1 diabetes and a mainstay for advanced type 2, with a century of evidence behind it. As a performance compound in healthy people, the story inverts: the human record is one of harm — hypoglycemic coma, irreversible brain injury, and death — with no good controlled evidence that it builds meaningful muscle. It is a prescription drug (older human insulins are OTC via the pharmacist in nearly all states), it is not a controlled substance, and it is banned in sport at all times under WADA S4.4.2. This is not a “manageable side-effect” situation: acute hypoglycemia can kill before help arrives.

Evidence grade: Strong human. Strong (overwhelming) for its medical indications in diabetes; the performance/anabolic use is not supported by efficacy evidence and is dominated by documented harm.